Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| SA-140857b | SA-140857b | U.S. | 1996 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | AZT | 18 |
| 2 | AZT+DDC+SQV | 42 |
| 3 | AZT+SQV | 16 |
| 4 | AZT+DDC+SQV | 17 |
| 5 | AZT+SQV | 65 |
| 6 | AZT+DDC+SQV | 4 |
| 7 | 3TC+AZT+DDC+SQV | 10 |
| 8 | 3TC+AZT+SQV | 9 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| G48V, I54IV, V82A | F53FL | L10I, K14R, L19LI, L63A, A71AV, I72V, T74S, V77I |
| >SA-140857b| codons 1-99 PQITLWQRPIVTIRIGGQIKEALLDTGADDTVLEEMNLPGRWKPKMIVGIGGLVKVRQYD QIAIEICGHKVVGSVLIGPTPANIIGRNLLTQIGCTLNF |
References
| Author | Title | Citation |
| Sevin, AD | Methods for investigating the relationship between drug-susceptibility phenotype and HIV-1 genotype with applications to ACTG 333. | J Infect Dis, 2000 |
| Wu, TD | Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. | J Virol, 2003 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |